Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

<p>Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.</p

Introduction: The Law-Medicine Center 50th Anniversary Symposium: The Field of Health Law: It’s Past and Future

Introduction to The Law-Medicine Center 50th Anniversary Symposium: The Field of Health Law: Its Past and Future, Cleveland, Ohio 2004

Additional file 7: Table S5. of Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

Gene set enrichment analysis of down-regulated genes (DOCX 18 kb

Additional file 5: Figure S1. of Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

Subsampling analysis. This analysis subsampled pairs of non-responders (Comparison 3) to random groups of 6 patients 100 times. Comparison 1 and Comparison 3 shows the number of differentially expressed genes in the paired comparison analysis of responders and non-responders, respectively (DOCX 51 kb